Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
Status:
RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.